UNSPSC 51373473: Hydrocodone/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373473 Hydrocodone/phenylephrine/pyrilamine is a Commodity code that nominally designates a specific pharmaceutical combination, but recent state and local solicitations under this code show little alignment with the product name itself. The most recent opportunities tagged to this code involve procurement of naloxone (an opioid antagonist unrelated to hydrocodone combination products) and cooperative purchasing frameworks for generic multi-source pharmaceuticals and over-the-counter products. State and local issuing bodies posting under this code include county health departments and multi-state cooperative purchasing alliances, though the mismatch between the code's nominal scope and the actual work being solicited suggests either miscoding at the source or use of this code as a catch-all placeholder for pharmaceutical procurement more broadly.

Recent opportunities show activity in Florida and Minnesota, with the most notable being Seminole County's July 2026 IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries (due July 26, 2023, per the posted solicitation), and the Minnesota Multistate Cooperative Purchasing Alliance's January 2026 RFP to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions, with proposals due March 26, 2026. The lack of clear connection between the UNSPSC code name and the actual procurement activity warrants verification of coding accuracy before pursuing opportunities tagged to this code.